Larimar Therapeutics
Price & Volume
Stats
See moreOpen | $4.23 |
Previous Close | $4.15 |
Day Range | $4.18-$4.47 |
52W Range | $1.61-$9.50 |
Market Cap | $436M |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.02 |
News
See moreYahoo Finance • 3 days ago
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
Yahoo Finance • 4 days ago
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Yahoo Finance • 29 days ago
TNA: ETF Outflow Alert
Yahoo Finance • 2 months ago
Larimar Therapeutics GAAP EPS of -$0.41 beats by $0.07
About
CEO | Dr. Carole S. Ben-Maimon M.D. |
CFO | Mr. Michael Celano CPA |
Address | Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 65 |
